Based on typical FDA review timelines and the current progress of trials, analysts project: Phase 3 trial completion: Late 2025 to early 2026 FDA submission: First half of 2026 Potential FDA approval: Q3 2026 to Q1 2027 Commercial availability: 2-3 months post-approval The FDA has not granted any special designations (Breakthrough Therapy, Fast Track) for Retatrutides obesity indication, which may mean standard review timelines apply
Versus sulphonylureas (such as gliclazide), GLP-1 receptor agonists offer comparable glucose-lowering efficacy but with significantly lower hypoglycaemia risk and the advantage of weight loss rather than weight gain
Gastroparesis symptoms include acid reflux and stomach pain
To support this transition, Ypsomed has applied its net zero sustainability principles to multidose injection systems as well
These occur most often during dose increases and typically diminish as the body adjusts
If youve never traveled with refrigerated medication before, youre probably wondering how traveling with semaglutide or tirzepatide works
